Not finding it? Sign in to also search OpenAlex live.
-
Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda2020 Blood article Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes
Raymond L. Comenzo, Efstathios Kastritis, Giovanni O. Palladini, Monique C. Minnema, Ashutosh D. Wechalekar, Arnaud Jaccard, +27 more
15citations -
Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study2024 Inflammatory Bowel Diseases article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access cited by 2 patents
Hiroshi Nakase, Silvio Danese, Walter Reinisch, Timothy E. Ritter, Yan Liang, Emily Wendt, +10 more
5citations -
Determination of the concentration range for 267 proteins from 21 lots of commercial human plasma using highly multiplexed multiple reaction monitoring mass spectrometry2020 The Analyst article Chemistry Advanced Proteomics Techniques and Applications Open access cited by 3 patents
Claudia Gaither, Robert Popp, Yassene Mohammed, Christoph H. Borchers
51citations -
Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study2021 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes
Raymond L. Comenzo, Giovanni O. Palladini, Efstathios Kastritis, Monique C. Minnema, Ashutosh D. Wechalekar, Arnaud Jaccard, +24 more
12citations